Omnicell (OMCL) Releases Earnings Results, Beats Expectations By $0.06 EPS

Omnicell (OMCL) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $0.38 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $0.32. The company posted revenue of $175.60 million in the period, compared to analysts expectations of $170.88 million. The company’s revenue was up 55.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.28 EPS.

Many Wall Street Analysts have commented on Omnicell. Company shares were Reiterated by FBR Capital on Jul 7, 2016 to “Outperform”, Firm has raised the Price Target to $ 40 from a previous price target of $35 .

Omnicell (OMCL) witnessed a volatile trading activity on Thursday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $36.37 and reached the intraday high at $36.48. The bulls started the profit booking and pushed the shares to intraday low of $36.21. The trading session was marked by a volume range of 1,19,406 shares exchanging hands. The 52-week high of the shares is $40.39 and the 52-week low is $25.06. The market cap of the company stands at $1,301 M and there are 3,59,17,793 shares in public circulation.

In a different news, on Jul 7, 2016, Robin Gene Seim (EVP, Global A & M Adherence) sold 5,302 shares at $34.75 per share price. According to the SEC, on Jun 6, 2016, Jorge R. Taborga (Executive VP. Engineering) sold 25,979 shares at $33.00 per share price. On May 25, 2016, Gary S Petersmeyer (director) sold 6,250 shares at $31.22 per share price, according to the Form-4 filing with the securities and exchange commission.

Omnicell Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company has two operating segments: Automation and Analytics and Medication Adherence. The Automation and Analytics segment is organized around the design manufacturing selling and servicing of medication and supply dispensing systems pharmacy inventory management systems and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards packaging equipment and ancillary products and services. The Company’s products include OmniRx SinglePointe AnywhereRN OptiFlex MS OptiFlex CL AccuFlex Autobond AutoGen and SureSeal among others.


Leave a Reply

Omnicell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omnicell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.